ArticleInternational journal of genomics2025
Identification and Validation of the Key Genes of Diabetic Vasculopathy: Evidence Based on Bioinformatics Analysis and Animal Study.
Article in International journal of genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and Validation of the Key Genes of Diabetic Vasculopathy: Evidence Based on Bioinformatics Analysis and Animal Study.International journal of genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: The mechanisms contributing to diabetic vasculopathy have not been fully understand. Methods: First, we identified differentially expressed genes (DEGs) of diabetic vasculopathy via GSE13760. Enrichment analysis was conducted. We utilized the cMAP database to identify potential small-molecular drugs targeting diabetic vasculopathy based on upregulated DEGs. Hub genes were extracted from protein-protein interaction (PPI) networks, and their expression and correlation patterns were further evaluated. Key genes implicated in diabetic vasculopathy were determined by integrating three distinct algorithmic approaches. Additionally, we constructed mRNA-miRNA and mRNA-transcription factor (TF) regulatory networks and performed immune infiltration as well as single-cell RNA sequencing (scRNA-seq) analyses. Finally, animal studies were carried out to provide preliminary experimental validation. Results: One hundred thirty-nine DEGs were identified in the comparison between Type 2 diabetes mellitus (T2DM) and control (Con) arterial samples. Then, enrichment analysis revealed that the DEGs were associated with several key pathways, including cytokine-cytokine receptor interaction, regulation of phosphatidylinositol 3-kinase activity, and the TGF-beta signaling pathway. Ten leading small-molecular compounds with therapeutic potential for diabetic vasculopathy were identified. Among the upregulated genes, BMP4 and LEP were selected as key candidates. Regulatory network analyses, including mRNA-miRNA and mRNA-TF interactions, along with immune infiltration profiling, suggested that multiple miRNAs, TFs, and immune cells may collectively influence BMP4 and LEP expression. scRNA-seq further indicated predominant expression of BMP4 within endothelial cells and fibroblasts. Finally, experimental validation in the T2DM mouse model corroborated the expression patterns of these key genes and enrichment findings. Conclusions: Findings indicate that the two upregulated genes, BMP4 and LEP, are implicated in the pathophysiology of diabetic vasculopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.